Cargando…
Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed
Oxidised low density lipoprotein (LDL) was considered to be important in the pathogenesis of atherosclerosis, but the large clinical trials of antioxidants, including the first one using probucol (the PQRST Trial), failed to show benefit and have cast doubt on the importance of oxidised LDL. We have...
Autores principales: | Ahmad, Feroz, Leake, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ireland Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989656/ https://www.ncbi.nlm.nih.gov/pubmed/29518380 http://dx.doi.org/10.1016/j.chemphyslip.2018.03.001 |
Ejemplares similares
-
Oxidation of Low-Density
Lipoprotein by Iron at Lysosomal
pH: Implications for Atherosclerosis
por: Satchell, Leanne, et al.
Publicado: (2012) -
Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages
por: Ahmad, Feroz, et al.
Publicado: (2019) -
Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice
por: Wen, Yichuan, et al.
Publicado: (2019) -
Why do antioxidants fail to provide clinical benefit?
por: Warnholtz, Ascan, et al.
Publicado: (2000) -
Glucose as a Major Antioxidant: When, What for and Why It Fails?
por: Cherkas, Andriy, et al.
Publicado: (2020)